Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
…, L Tian, I Kulikovskaya, M Gupta, DE Ambrose… - Nature, 2022 - nature.com
The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated
potential for treatment of various cancers 1 , 2 , 3 , 4 , 5 , 6 – 7 . However, little is known …
potential for treatment of various cancers 1 , 2 , 3 , 4 , 5 , 6 – 7 . However, little is known …
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
…, WT Hwang, E Pequignot, DE Ambrose… - Nature medicine, 2018 - nature.com
Tolerance to self-antigens prevents the elimination of cancer by the immune system 1 , 2 .
We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance …
We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance …
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion
with CD19 – leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was …
with CD19 – leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was …
PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
…, JJ Melenhorst, SF Lacey, DE Ambrose… - Blood, The Journal …, 2017 - ashpublications.org
Antibodies blocking the programmed death 1 receptor (PD-1) on T cells produce tumor
regression in multiple cancers by disrupting the PD-L1/PD-1 (programmed death-ligand 1/…
regression in multiple cancers by disrupting the PD-L1/PD-1 (programmed death-ligand 1/…
[HTML][HTML] Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for …
Background: CART-BCMA is an autologous T cell product engineered by lentiviral transduction
to express a fully human BCMA-specific CAR with CD3ζ and 4-1BB signaling domains …
to express a fully human BCMA-specific CAR with CD3ζ and 4-1BB signaling domains …
[HTML][HTML] B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I …
…, E Lancaster, DT Vogl, K Dengel, DE Ambrose… - Blood, 2016 - Elsevier
Background: BCMA is expressed on MM cells, and CAR T cells targeting BCMA have pre-clinical
anti-MM activity. CART-BCMA is an autologous T cell product engineered by lentiviral …
anti-MM activity. CART-BCMA is an autologous T cell product engineered by lentiviral …
Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-Bcma CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with …
…, EA Stadtmauer, SF Lacey, K Dengel, DE Ambrose… - 2016 - ashpublications.org
Neurologic toxicity has been observed with anti-CD19 chimeric antigen receptor (CAR) T
cells and the anti-CD19 BiTE blinatumomab. Both focal (eg, cranial nerve palsy) and global (eg…
cells and the anti-CD19 BiTE blinatumomab. Both focal (eg, cranial nerve palsy) and global (eg…
[HTML][HTML] Pilot study of anti-CD19 chimeric antigen receptor T cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple …
…, NDS Kerr, SF Lacey, JJ Melenhorst, DE Ambrose… - Blood, 2016 - Elsevier
Background: Though CD19 is expressed only rarely on multiple myeloma (MM) plasma cells
(PC), rare CD19+ B cells can be identified in MM patients that are clonally related to the MM …
(PC), rare CD19+ B cells can be identified in MM patients that are clonally related to the MM …
[HTML][HTML] Long-term functional persistence, B cell aplasia and anti-leukemia efficacy in refractory B cell malignancies following T cell immunotherapy using CAR …
…, JM Finklestein, M Gupta, I Kulikovskaya, DE Ambrose… - Blood, 2013 - Elsevier
Background Recent advances in T cell engineering have enabled clinical trials to evaluate
the potential for adoptive transfer of T cells to target malignancy. A single treatment with …
the potential for adoptive transfer of T cells to target malignancy. A single treatment with …
Efficacy and safety of humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 in children with relapsed/refractory ALL
SL Maude, DM Barrett, DE Ambrose, SR Rheingold… - 2015 - ashpublications.org
Background Targeted immunotherapy with T cells expressing a chimeric antigen receptor (CAR)
can produce dramatic anti-tumor responses. We previously demonstrated complete …
can produce dramatic anti-tumor responses. We previously demonstrated complete …